Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals

Lifelines cohort study, DiscovEHR/MyCode study, VA Million Veteran Program, Thomas W. Winkler, Humaira Rasheed, Alexander Teumer, Mathias Gorski, Bryce X. Rowan, Kira J. Stanzick, Laurent F. Thomas, Adrienne Tin, Anselm Hoppmann, Audrey Y. Chu, Bamidele Tayo, Chris H.L. Thio, Daniele Cusi, Jin Fang Chai, Karsten B. Sieber, Katrin Horn, Man LiMarkus Scholz, Massimiliano Cocca, Matthias Wuttke, Peter J. van der Most, Qiong Yang, Sahar Ghasemi, Teresa Nutile, Yong Li, Giulia Pontali, Felix Günther, Abbas Dehghan, Adolfo Correa, Afshin Parsa, Agnese Feresin, Aiko P.J. de Vries, Alan B. Zonderman, Albert V. Smith, Albertine J. Oldehinkel, Alessandro De Grandi, Alexander R. Rosenkranz, Andre Franke, Andrej Teren, Andres Metspalu, Andrew A. Hicks, Johanna Kuusisto, Kjell Nikus, Leo Pekka Lyytikäinen, Mika Kähönen, Nina Hutri-Kähönen, Nina Mononen, Pashupati P. Mishra, Peter Kovacs, Terho Lehtimäki

Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

Abstrakti

Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.

AlkuperäiskieliEnglanti
Artikkeli580
Sivumäärä20
JulkaisuCommunications biology
Vuosikerta5
DOI - pysyväislinkit
TilaJulkaistu - kesäk. 2022
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Sormenjälki

Sukella tutkimusaiheisiin 'Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä